ACHE and Alzheimer disease: The currently existing type of therapeutic intervention is restricted to AChE inhibitors (AChEIs) such as donepezil, rivastigmine, galantamine, and tacrine (latter was discontinued because of toxicity) and the newly approved Aβ modulator aducanumab.7,8 Though AChEIs do not stop the advancement of the disease, they have shown usefulness in alleviating cognitive functions associated with learning and memory and form the major pharmacological agents in the management of the AD.9,10